×

Transdermal and/or topical delivery system comprising clobazam

  • US 10,449,201 B2
  • Filed: 07/28/2016
  • Issued: 10/22/2019
  • Est. Priority Date: 08/17/2015
  • Status: Active Grant
First Claim
Patent Images

1. A Transdermal drug delivery system (TDDS) for administration of clobazam to a patient comprising:

  • an active substance area or reservoir comprising a pharmaceutical composition comprisingabout 4% to about 6% Clobazam;

    about 20% to about 25% diethylene glycol monoethyl ether;

    about 10% to about 12% triacetin;

    about 10% to about 25% of a surfactant selected from the group consisting of caprylocaproyl polyoxyl-8 glycerides, polyethylene glycol sorbitan monolaurate, propylene glycol monolaurate, and mixtures thereof;

    about 5% to about 6% Lactic Acid;

    about 10% to about 15% glycol;

    about 20% to about 35% mixture of dimethylsulfoxide and dimethylisosorbide;

    about 0.1% to about 5% gelling agent;

    about pH 5.0 to about 6.0, wherein the percentage of components are weight to weight of the composition,further wherein the TDDS comprises an impermeable backing layer and a releasing membrane, which is covered by a detachable protective layer,and further wherein the application period of the TDDS is 7 days.

View all claims
  • 5 Assignments
Timeline View
Assignment View
    ×
    ×